Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1095MR)

This product GTTS-WQ1095MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1095MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8129MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ14770MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ9958MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ15004MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ11613MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ10190MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ219MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ15020MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SNDX-6352
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW